Note: Eligibility for Samsung’s SmartStarts program requires newcomers to possess* one of the following Immigration, Refugees ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting ...

Novo Nordisk plans a new trial for its experimental drug, CagriSema, in 2025 after recent trials failed to meet weight-loss expectations. Despite aiding patients to reduce weight by 22.7%, it fell ...

UBS analyst Trung Huynh says Novo Nordisk’s CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly and Amgen . CagriSema achieved an ave ...

Novo Nordisk announced plans for a new trial of its CagriSema drug to explore its weight-loss potential further in 2025. The decision follows disappointing results from a late-stage trial that showed ...

Outside the U.S., Ipsen will continue distributing Increlex® during a six-month transition period, after which Eton will take over commercialization. The transaction was financed by Eton’s cash on ...